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The leukocyte immunoglobulin-like receptors contains   receptors 
possessing extra cellular immunoglobulin domains .
They are also known as CD85,ILTs and LIR, and can exert 
immuno modulatory effects on a wide range of immune cells .
LILR S family:
Leukocyte IG like receptors are also   expressed predominantly  
on monocytes and B cells .
The leukocyte Ig-like receptor (LILR/ILT/LIR) family comprises 
13 members regulating a broad range of cells in the immune 
responses. They can recognize MHC (major histocompatibility 
complex) class I molecules
   INTRODUCTION
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Leukocyte immunoglobulin receptor sub 
family A member 3(LILRA3):
   LILRA3 is highly homologous to other LILR genes and  bind with the 
 human leukocyte antigen (HLA) class I and acts as a soluble receptor for 
class -1 molecules.
.
  LILRA3 is the only secretary LILR and  control the inhibitory 
immune response induced by LILRB1, LILRB2, and other HLA-binding 
LILR molecules like LILRA1.
 LILRA3 gene located receptor complex on chromosome         19q13.4. 
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               Disease  related to LILRA3
LILRA3 impair interactions on membrane-bound LILRs with their HLA 
ligands, thus modulating immune responses and leads to HLA class-1 associated 
diseases
 The increased levels of LILRA3 in serum of patients with RA(Rheumatoid 
Arthritis), monocytes  and B cells from patients with RA show increased 
expression of LILRA3 mRNA. These suggest that lymphocyte and/or monocyte-
derived LILRA3 play a role of  inflammation in RA.
 The Elevated  levels of  LILRA3 in RA patients   leads to stroke.
 RA  is an autoimmune disease leading to chronic inflammation of the joints 
affecting the synovial membrane, cartilage and bone.
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    To identify a novel inhibitor for leukocyte immunoglobulin 
         receptor  subfamily  A member3 against stroke in RA
                                patients
 OBJECTIVES
 Sequential and functional analysis  of the  protein LILRA3
 Building a 3D model for LILRA3 using Modeller 9V9.
 Docking Analysis of LILRA3 using SCHRODINGER 
software
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sequence
MTPILTVLICLGLSLDPRTHVQA
GPLPKPTLWAEPGSVITQGSPVT
LRCQGSLETQEYHL
 
BLASTp
Target and template alignment
Model building
Model evaluation
Multiple templates
1GOX 3P2T
Docking
  Model visualization
Ligand database
In house library
Template selection
Query coverage 
93 and 92%
Identity 39 and 
45%
Docking complex
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           VALIDATION RESULTS
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 PROSA  tool  graph showed all over model quality of the 
structure and the location of the Z-score for the structure
 The Z-score of LILRA3 was present in the range represented 
in  black dot
PROSA RESULT
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CAST p   Results
 The ligand binding sites were estimated through 
CASTp analysis. Binding sites from CASTp analysis are
Ser -338,Glu-360,Ser-389,
Ala-392,Gly-393,Thr-394,
Glu-416,Leu-417,Val-418,
Val-419,421-Gly,422-Ala,
423-Ala,424-Glu,425-Thr,
426-Leu,427-Ser,428-Pro,
429-Pro,430-Gln,432-Lys,
433-Ser,434-Asp,435-Ser,
436-Leu,439-Glu.
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Docking is frequently used to predict the binding orientation of 
small molecule / drug candidates to their protein targets in order 
to predict the affinity of the small molecule. 
P
L
P
Docking
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      Modeled  LILRA3 
protein 
11,693 Analogues
 Protein and ligand preparation 
 Post Ligprep  1741 Compounds
Lipinski filter Reactive filter
     676 and 558 compounds
Virtual screening through HTVS ,sp and XP 
dock(315, 125 and 32)
    17  leads
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Docking score plot of ligand and leads
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 Docking complex of lead 1 with LILRA3 protein with 
an negative XP G Score of -10.70 K cal/mol
Docking Complex
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Hydrogen bond network of lead “1” with LILRA3 protein
The lead1 forms 4 hydrogen bonds Thr 425, Glu -360, Ser-433,Val-419. 
The first hydrogen bond forms a bond length of 2.106. The second 
hydrogen has 2.040 length and third one has 2.064 and the fourth has 
2.080 bond lengths respectively . The other van der Waal residues like 
Val-418,Gly-393,Asp-434, Ser-433,Lys -432 forms hydrogen bond 
network
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 Mizoribine (trade name Bredinin) is 
an immuno suppresive drug. It is a natural 
product, first isolated from the mould 
Eupenicillium brefeldianum.
The lead “1” obtained is identified  
as MIZORIBINE
.
Mizoribine as potent Lead
Eupenicillium brefeldianum, an ascomycetes harvested 
from the soil of Hachijo Island, Tokyo, Japan, in 1971, 
produces mizoribine (MZB). MZB is a nucleoside of the 
imidazole class, and was found to have weak antimicrobial 
activity against Candida albicans, but it proved ineffective 
against experimental candidiasis
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    Conclusion
The over expression  of LILRA3 in serum of patients with 
RA show lymphocyte  suppression leads to stroke .
The lead ‘1’obtained (mizoribine) have better    binding 
affinity, good docking score and orientation with LILRA3  for 
the suppression  of lymphocyte in RA.
 Hence lead’1’(mizoribine) can be suggested as a promising 
lead for the treatment of RA  patients causing stroke.
 LILRA3 belongs to Ig family consisting of 439 amino 
acids
 The  function  of LILRA3 is to  act as soluble receptor 
for class1 MHC antigens.
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